tirzepatide and type 2 diabetes monotherapy in Chinese patients with early diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO) Read now: The SURPASS-EARLY trial

It has also been banned by the US Anti-Doping Agency and the World Anti-Doping Agency

Understanding what distinguishes a genuinely clinical program one that addresses the physiological drivers of weight gain from a prescription service is the starting point for making an informed decision

While early studies show good results, larger and more standardized clinical trials are still needed to fully understand its long-term benefits and the best treatment settings for different types of patients

Market pressures, industry particularities, and the unique nature of GLP1s are impacting the legislative tilt, but the dust has yet to settle

In fact, there is evidence to suggest that activating these GLP-1 receptors may affect dopamine levels

The one thats best for you depends entirely on what youre optimizing for at breakfast, and that can shift day to day